RxDoctor Payments Data

Howard Rosas, DPM

Podiatry · New York, NYNPI 1285785147

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Amgen at 26.4% of the total. Reporting peaked in 2023 at $941 and has fallen 72.1% since, to $262 in 2025. Among podiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,902in general payments, 2019–2025

Across 31 payments — averaging $93.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$766
  • Abbott$337
  • Paratek Pharmaceuticals, Inc.$265
  • Averitas Pharma Inc.$255
  • Smith+Nephew$174
  • Nevro Corp.$144
  • plus $961 from 9 others

What the payments were for

  • Food & beverage$2,902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,902 in reported general payments places this provider in the 95th percentile of 225 podiatry providers in New York.

See all podiatry providers in New York

Medicare billing

Part B allowed, 2024
$74,545
Medicare patients
288
Services billed
792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ammonium Lactate781$14,073
Clotrimazole388$13,667
Clobetasol Propionate15$4,355
Ketoconazole111$3,912
Silver Sulfadiazine346$2,589
Triamcinolone Acetonide186$1,568
Diclofenac Sodium73$1,128
SsdSilver Sulfadiazine131$921
CiclopiroxCiclopirox Olamine20$620
NyamycNystatin14$534
NystopNystatin12$516
Nystatin17$395
Gabapentin75$388
Colchicine11$260
Ciclopirox13$241

Paid to pharmacies, not to this prescriber.

Other podiatry in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →